Cingulate Inc. - Warrants (NQ:CINGW)

0.0060 -0.0035 (-36.84%)

Streaming Delayed Price Updated: 11:28 AM EDT, Sep 1, 2026 Add to My Watchlist

Price and Volume

Volume	2,915
Open	0.0076
Bid (Size)	0.0060 (100)
Ask (Size)	0.0092 (1,000)
Prev. Close	0.0095
Today's Range	0.0060 - 0.0076
52wk Range	0.0051 - 0.1200
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

September 05, 2023

Data Accepted as Finalist for First Annual Poster Awards

From Cingulate Inc.

Via GlobeNewswire

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

August 14, 2023

From Cingulate Inc.

Via GlobeNewswire

Performance

YTD	-90.0%	-90.0%
1 Month	-45.9%	-45.9%
3 Month	-85.0%	-85.0%
6 Month	-86.3%	-86.3%
1 Year	-89.3%	-89.3%

More News

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

July 11, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

June 29, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

June 08, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate to Present at 13th Annual LD Micro Invitational

May 25, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate, Indegene to Participate in Benzinga All Live Access Event

May 12, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

May 10, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

May 03, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate to Participate in Benzinga All Live Access Event

April 14, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

April 04, 2023

From Cingulate Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Cingulate Inc. - Warrants publicly traded?

Yes, Cingulate Inc. - Warrants is publicly traded.

What exchange does Cingulate Inc. - Warrants trade on?

Cingulate Inc. - Warrants trades on the Nasdaq Stock Market

What is the ticker symbol for Cingulate Inc. - Warrants?

The ticker symbol for Cingulate Inc. - Warrants is CINGW on the Nasdaq Stock Market

What is the current price of Cingulate Inc. - Warrants?

The current price of Cingulate Inc. - Warrants is 0.0060

When was Cingulate Inc. - Warrants last traded?

The last trade of Cingulate Inc. - Warrants was at 09/01/26 11:28 AM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.